Treatment pathways in Finnish patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH)
Authors:
- Markku PentikäinenMPMarkku Pentikäinen
- Terttu HarjuTHTerttu Harju
- Christian AsseburgCAChristian Asseburg
- Erkki SoiniESErkki Soini
- Christina WennerströmCWChristina Wennerström
- the FINPAH study groupTGthe FINPAH study group
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Pulmonary Circulation
- Vol. 15 (1) , e12440
Abstract
Treatment patterns of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in Finland are unknown. Guidelines now recommend early escalation of treatment for PAH. We evaluated how well Finnish practice follows guidelines, and how treatment initiations and outcomes are related. The pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in Finland cohort includes all PAH and CTEPH patients diagnosed between 2008 and 2020 in all Finnish university hospitals. Drug therapy was analysed in patients with medical/procedural history available, and changes in the 4‐tier comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA) 2.0 risk score were evaluated. PAH patients (n = 268) were initially treated with monotherapy (52%) or double therapy (24%). After year 2015, double therapy use increased to 39%. PAH treatment at 1 year after diagnosis included phosphodiesterase 5 inhibitors (71%), endothelin‐receptor antagonist (48%), prostacyclin analogue (7%), calcium channel blocker (12%) and selexipag (1%). 35% achieved low risk at 1 year, increasing to 44% for patients diagnosed after 2015. Those remaining at intermediate‐high (IH) or high risk (H) (28%) were not treated less aggressively than others but were older, had more comorbidities, and often history of smoking. CTEPH patients (n = 189) were treated with pulmonary endarterectomy (PEA) (27%), balloon pulmonary angioplasty (BPA) (11%) and medical therapy only (41%) within 1 year from diagnosis. 45% achieved low risk at 1 year. We present additional results on treatment of IH and H patients, patient characteristics preceding death, and treatment persistence. We found less treatment of PAH patients with double or triple therapies and of CTEPH patients with PEA and BPA than expected but with good results. Patients not reaching low or intermediate COMPERA 2.0 were old and had comorbidities.Keywords
This publication has 23 references indexed in Scilit:
- Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertensionEuropean Respiratory Journal, 2018
- The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroupsThe Journal of Heart and Lung Transplantation, 2017
- Characteristics and survival of adult Swedish PAH and CTEPH patients 2000–2014Scandinavian Cardiovascular Journal, 2016
- Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary HypertensionCirculation, 2016
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2015
- Causes and Circumstances of Death in Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Riociguat for the Treatment of Chronic Thromboembolic Pulmonary HypertensionNew England Journal of Medicine, 2013
- Chronic Thromboembolic Pulmonary Hypertension (CTEPH)Circulation, 2011
- Pulmonary Hypertensive Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension Before Pulmonary ThromboendarterectomyCirculation, 2009
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991